Protein production and sequencing to study antibody-related low platelet conditions
Official title: Protein Production, Structural Biology, and Nucleic Acid Sequencing and Analysis
Funded at Versiti Blood Health, INC. · NIH-11372199 · Data updated 2026-11-12
A multi-project effort at Versiti Blood Health to understand how certain antibodies and platelet proteins cause dangerous low-platelet conditions, using protein production, structural biology, and advanced 16S sequencing technologies.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Blood Health, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $498,143 |
| NIH project number | 5P01HL167668-03 |
| Project ID | NIH-11372199 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with antibody-mediated thrombocytopenia or related platelet disorders who may benefit from improved understanding and future therapeutic approaches.
✕Less likely to help
Participants in this grant are primarily researchers and biological materials; direct patient benefit would come through future advances, not immediate treatment.
What this research studies
This program brings together experts to produce and study antibodies and platelet antigens like PF4 and PBPi, map how they interact with β3 integrins, and use next-generation sequencing to trace how harmful B cells arise. It aims to share standardized materials and data across three linked projects, speeding up discovery and ensuring results are reproducible. Patients with antibody-mediated thrombocytopenias could benefit from clearer mechanisms and future targeted therapies arising from these insights.
Why it matters
Potential benefit: If successful, the work could lead to better understanding of the disease process and inform development of targeted diagnostics or treatments for antibody-mediated thrombocytopenia.
How similar studies have gone: Previous similar approaches have advanced understanding of antibody–antigen interactions and informed therapeutic strategies in related platelet disorders.
Where this research is happening
-
Versiti Blood Health, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Zhu, Jieqing — Versiti Blood Health, INC.
- Study coordinator: Zhu, Jieqing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.